TradingView Indicator and Backtesting Toolkit

Digital products

It sells indicators, chart overlays and strategy-testing tools that traders add to TradingView, and revenue grew 120% over the past year.

Ask $8M · Profit $1M · 8.0x · Acquire.com

Oct 27

Label: Worth Studying
Reason: Big, profitable and growing fast, but founded in January 2023, too young to rate as a purchase, and 8.0x profit is a steep price.

$1M profit on $3.1M revenue over the last 12 months, a 32% margin, with 120% annual growth reported on the listing page.
Bootstrapped to 1,000-5,000 customers since its January 2023 founding, with no outside funding to unwind.
The toolkit covers indicators, chart overlays, strategy backtesting and automation, so customers likely use it across several steps of their trading rather than for one signal.

Last month showed $10.5K profit on $254K revenue, against an average of about $83K profit a month over the 12 months; this suggests costs have jumped or profit is uneven, and the $1M figure needs explaining before it is trusted.
The listing reports $0 recurring revenue and churn of 10% or more, which suggests sales are one-off or short-lived rather than lasting subscriptions.
Everything runs on TradingView, a platform the business does not control; a change to its rules for third-party scripts could cut sales overnight.
At 8x the last 12 months' profit, and far more on last month's profit, the price assumes the recent growth continues.

A buyer with several million dollars and experience marketing to traders, willing to carry dependence on a single charting platform.

Why did profit fall to $10.5K on $254K revenue last month, and is that cost level ongoing?
How is the toolkit sold (one-off licences, lifetime access or subscriptions), given the listing shows no recurring revenue?
What agreement or TradingView policy governs selling these scripts, and has TradingView ever restricted any of them?

Oct 27Added to Acumen Wire